ACE2 and COVID-19: In the context of ACE2 overexpression, viral entry into and replication within human cells may be enhanced, and the previous equilibrium of the RAAS system may be altered favoring a more severe course of COVID‐19 in the group of patients on prior RAAS inhibitor treatment as suggested by the results of this study (Figure 2).